Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Assets Average (2016 - 2026)

Ani Pharmaceuticals' Assets Average history spans 15 years, with the latest figure at $1.4 billion for Q4 2025.

  • On a quarterly basis, Assets Average rose 10.76% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 10.76% increase, with the full-year FY2025 number at $1.4 billion, up 24.49% from a year prior.
  • Assets Average hit $1.4 billion in Q4 2025 for Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Over the last five years, Assets Average for ANIP hit a ceiling of $1.4 billion in Q4 2025 and a floor of $462.5 million in Q1 2021.
  • Historically, Assets Average has averaged $900.1 million across 5 years, with a median of $843.5 million in 2023.
  • Biggest five-year swings in Assets Average: dropped 1.49% in 2021 and later surged 63.93% in 2022.
  • Tracing ANIP's Assets Average over 5 years: stood at $621.0 million in 2021, then increased by 20.7% to $749.6 million in 2022, then increased by 19.69% to $897.2 million in 2023, then skyrocketed by 43.33% to $1.3 billion in 2024, then increased by 10.76% to $1.4 billion in 2025.
  • Business Quant data shows Assets Average for ANIP at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.